Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · Real-Time Price · USD
34.13
-0.40 (-1.16%)
At close: Nov 4, 2025, 4:00 PM EST
34.00
-0.13 (-0.38%)
After-hours: Nov 4, 2025, 7:07 PM EST
Travere Therapeutics Employees
Travere Therapeutics had 385 employees as of December 31, 2024. The number of employees increased by 5 or 1.32% compared to the previous year.
Employees
385
Change (1Y)
5
Growth (1Y)
1.32%
Revenue / Employee
$1,132,016
Profits / Employee
-$229,971
Market Cap
3.05B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 385 | 5 | 1.32% |
| Dec 31, 2023 | 380 | -82 | -17.75% |
| Dec 31, 2022 | 462 | 152 | 49.03% |
| Dec 31, 2021 | 310 | 48 | 18.32% |
| Dec 31, 2020 | 262 | 41 | 18.55% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
TVTX News
- 5 hours ago - Travere Therapeutics to Participate at Upcoming Investor Conferences - Business Wire
- 4 days ago - Top 2 Health Care Stocks That May Fall Off A Cliff This Quarter - Benzinga
- 5 days ago - Travere Therapeutics, Inc. (TVTX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - Travere Therapeutics Reports Third Quarter 2025 Financial Results - Business Wire
- 12 days ago - Travere Therapeutics to Report Third Quarter 2025 Financial Results - Business Wire
- 18 days ago - Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2025 - Business Wire
- 25 days ago - Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 5 weeks ago - CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy - Business Wire